Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 1,181 Cr.
- Current Price ₹ 2,005
- High / Low ₹ 2,835 / 1,591
- Stock P/E 59.4
- Book Value ₹ 411
- Dividend Yield 0.07 %
- ROCE 16.4 %
- ROE 12.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 89.7% CAGR over last 5 years
Cons
- Working capital days have increased from 88.4 days to 181 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 12 | 18 | 25 | 45 | 64 | 79 | |
| 12 | 18 | 21 | 34 | 43 | 53 | |
| Operating Profit | 0 | 1 | 4 | 11 | 20 | 26 |
| OPM % | 3% | 4% | 17% | 23% | 32% | 33% |
| 1 | 1 | 1 | 2 | 4 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 |
| Profit before tax | 1 | 1 | 5 | 11 | 23 | 27 |
| Tax % | 27% | 25% | 26% | 26% | 25% | 25% |
| 1 | 1 | 3 | 8 | 17 | 20 | |
| EPS in Rs | 8.58 | 19.77 | 28.51 | 33.77 | ||
| Dividend Payout % | 0% | 0% | 0% | 3% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 47% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 90% |
| 3 Years: | 80% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 20% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 1 | 1 | 1 | 6 |
| Reserves | 2 | 3 | 6 | 18 | 81 | 236 |
| 0 | 0 | 0 | 8 | 1 | 4 | |
| 3 | 8 | 9 | 8 | 15 | 34 | |
| Total Liabilities | 5 | 11 | 16 | 35 | 98 | 280 |
| 0 | 0 | 0 | 3 | 2 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 3 | 21 | 43 | 209 |
| 5 | 11 | 12 | 11 | 53 | 64 | |
| Total Assets | 5 | 11 | 16 | 35 | 98 | 280 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1 | -0 | 5 | 5 | 2 | 16 | |
| -1 | -0 | -5 | -15 | -21 | -12 | |
| 0 | -0 | -0 | 12 | 39 | -1 | |
| Net Cash Flow | 1 | -0 | 0 | 2 | 21 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 50 | 71 | 43 | 39 | 87 | 72 |
| Inventory Days | 23 | 36 | 47 | 5 | 22 | 22 |
| Days Payable | 68 | 164 | 139 | 60 | 107 | 53 |
| Cash Conversion Cycle | 5 | -56 | -48 | -16 | 2 | 42 |
| Working Capital Days | 22 | -18 | -38 | 8 | 76 | 181 |
| ROCE % | 46% | 92% | 69% | 41% | 16% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
23 May 2025 - Remus reports FY25 revenue growth of 23% standalone, 191% consolidated; expands markets and product portfolio.
-
Copy of Newspaper Publication
22 May 2025 - Submission of newspaper clippings for postal ballot notice dispatch and e-voting information on May 22, 2025.
-
Notice Of Shareholders Meetings-XBRL
21 May 2025 - REMUS PHARMACEUTICALS LIMITED has informed about Notice of Shareholders Meeting for Postal Ballot
-
Shareholders meeting
21 May 2025 - Remus Pharma proposes 1:1 bonus share issue, doubling equity capital to Rs.11.78 Cr, via postal ballot.
-
Analysts/Institutional Investor Meet/Con. Call Updates
19 May 2025 - Audio recording of Remus Pharma's FY25 earnings call available; no new price sensitive info shared.
Annual reports
Concalls
-
May 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing